BofA notes that the FDA posted this morning the approval of Artix 2.0 to the 510k database and the firm confirmed the approval with Inari Medical (NARI). This timing is in line with expectations as Inari Medical’s planned to re-enter limited market release in Q4 and as of early September was in the final parts of the FDA process, notes the firm, which adds that the company will share more on the approval and launch on its upcoming Q3 call next week. BofA has a Buy rating and $68 price target on Inari shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NARI:
- Inari Medical partners with AVF, NBCA on DEFIANCE trial
- Inari Medical price target lowered to $46 from $55 at Truist
- Inari Medical director sells $1.83M in common stock
- Inari Medical initiated with a Hold at Stifel
- Inari Medical initiated with a Market Perform at Leerink
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
